14 results on '"Malignant Ovarian Neoplasm"'
Search Results
2. Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
- Published
- 2024
3. Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
- Author
-
National Cancer Institute (NCI)
- Published
- 2023
4. Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN
- Author
-
Oliver Dorigo, Associate Professor of Obstetrics and Gynecology
- Published
- 2018
5. YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
- Author
-
National Cancer Institute (NCI)
- Published
- 2018
6. Epidemiological overview of metastatic ovarian carcinoma: long-term experience of TOTSG database.
- Author
-
Hiroaki Kajiyama, Shiro Suzuki, Fumi Utsumi, Kimihiro Nishino, Kaoru Niimi, Mika Mizuno, Nobuhisa Yoshikawa, Michiyasu Kawai, Hidenori Oguchi, Kimio Mizuno, Osamu Yamamuro, Kiyosumi Shibata, Tetsuro Nagasaka, and Fumitaka Kikkawa
- Subjects
OVARIAN cancer ,TUMORS ,CARCINOMA ,EPIDEMIOLOGY ,PATHOLOGY - Abstract
Malignant ovarian neoplasm is one of the most lethal malignancies among cancers of the female reproductive system. Occasionally, these tumors originate from non-ovarian organs as metastatic lesions since the ovary is a frequent metastatic target of many cancers. However, there limited clinical information on metastatic ovarian carcinoma (MOC) and its hallmarks are unknown. During the period of 1986-2015, 4,284 patients with malignant ovarian neoplasm were identified using the Tokai Ovarian Tumor Study Group (TOTSG) database. Of these, excluding borderline malignant tumor, 3,478 patients with malignant ovarian cancer were extracted. The pathological slides were evaluated under central pathological review. Among them, a total of 143 (4.1%) patients with MOC were identified. The median age of patients with MOC was 54 (29-82) years. The most and second most frequent original tumors were colorectal (43%, N=62) and gastric (29%, N=42) carcinoma, respectively. The rates of carcinoma of the appendix, breast, and pancreas were 8, 6, and 4%, respectively. This is the one of the largest studies clarifying the rates of MOC among malignant ovarian neoplasms. Although the rate is low, we should keep in mind that MOC, particularly from colorectal and gastric cancer should be considered when encountering clinical practice of ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Is there any difference in insulin resistance status between cases of benign and malignant ovarian neoplasms? A study on surrogate markers of insulin resistance in Indonesian non-diabetic women.
- Author
-
Winarto, Hariyono, Habiburrahman, Muhammad, Febriana, Irene Shinta, Kusuma, Fitriyadi, Nuryanto, Kartiwa Hadi, Anggraeni, Tricia Dewi, Utami, Tofan Widya, and Putra, Andi Darma
- Subjects
- *
OVARIAN tumors , *BIOMARKERS , *INSULIN resistance , *SYSTOLIC blood pressure , *BENIGN tumors - Abstract
The association between insulin resistance (IR) and ovarian neoplasm is little known. The present study attempted to investigate the difference in clinicopathological characteristics, metabolic parameters, and IR prevalence between benign and malignant ovarian neoplasms. The cross-sectional study involved 52 non-diabetic women with benign (n=27) and malignant (n=25) diagnoses in a tertiary hospital in Indonesia. Fasting insulin level (FIL), homeostatic model assessment of IR and β-cell dysfunction (HOMA-IR and HOMA-β), fasting IR index (FIRI), and quantitative insulin sensitivity check index (QUICKI) were used as surrogate markers to evaluate IR. Parametric and nonparametric statistical tests were employed to analyze the different parameters between the two groups. Pearson or Spearman's rank test assessed the correlation between markers and clinical variables. Results revealed that patients with benign neoplasms were younger than those with malignant neoplasms (38.63 vs. 47.40 years; P=0.003) and had a higher median body mass index (BMI) than their counterparts (22.98 vs. 18.61 kg/m2; P=0.014). Different characteristics between benign and malignant neoplasm cases were found in menopausal status, ovary side affected, systolic blood pressure, and BMI classes. Endometrial cysts and mucinous carcinoma were the most often diagnosed benign and malignant neoplasms. Malignant neoplasms had a lower median HOMA-β score than benign neoplasms (49.33 vs. 75.79; P=0.011), indicating more severe β-cell dysfunction. No significant difference was observed in the prevalence of IR between benign and malignant ovarian neoplasms for the following values of each marker: FIL (25.9% vs. 12.0%), HOMA-IR (37.0% vs. 28.0%), FIRI (51.9% vs. 48.0%) and QUICKI (81.5% vs. 92.0%). The indicators of FIL, HOMA-IR, HOMA-β, FIRI, and QUICKI correlated with each other and confirmed the reliability of these surrogate markers for measuring IR status in ovarian neoplasms. In brief, benign ovarian neoplasms tended to have more IR when compared with malignant ovarian neoplasms. However, this difference was not statistically significant. [ABSTRACT FROM AUTHOR]
- Published
- 2023
8. Epidemiological overview of metastatic ovarian carcinoma : long-term experience of TOTSG database
- Author
-
Kajiyama, Hiroaki, Suzuki, Shiro, Utsumi, Fumi, Nishino, Kimihiro, Niimi, Kaoru, Mizuno, Mika, Yoshikawa, Nobuhisa, Kawai, Michiyasu, Oguchi, Hidenori, Mizuno, Kimio, Yamamuro, Osamu, Shibata, Kiyosumi, Nagasaka, Tetsuro, and Kikkawa, Fumitaka
- Subjects
malignant ovarian neoplasm ,metastatic ovarian cancer ,original organ ,epidemiology - Abstract
Malignant ovarian neoplasm is one of the most lethal malignancies among cancers of the female reproductive system. Occasionally, these tumors originate from non-ovarian organs as metastatic lesions since the ovary is a frequent metastatic target of many cancers. However, there limited clinical information on metastatic ovarian carcinoma (MOC) and its hallmarks are unknown. During the period of 1986–2015, 4,284 patients with malignant ovarian neoplasm were identified using the Tokai Ovarian Tumor Study Group (TOTSG) database. Of these, excluding borderline malignant tumor, 3,478 patients with malignant ovarian cancer were extracted. The pathological slides were evaluated under central pathological review. Among them, a total of 143 (4.1%) patients with MOC were identified. The median age of patients with MOC was 54 (29–82) years. The most and second most frequent original tumors were colorectal (43%, N=62) and gastric (29%, N=42) carcinoma, respectively. The rates of carcinoma of the appendix, breast, and pancreas were 8, 6, and 4%, respectively. This is the one of the largest studies clarifying the rates of MOC among malignant ovarian neoplasms. Although the rate is low, we should keep in mind that MOC, particularly from colorectal and gastric cancer should be considered when encountering clinical practice of ovarian cancer.
- Published
- 2019
9. Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers
- Author
-
Renzo Barbazza, Serena Bonin, L. Bortot, Giorgio Stanta, Eros Azzalini, Fabio Puglisi, Vincenzo Canzonieri, Michele Bartoletti, Giorgio Giorda, Azzalini, Ero, Barbazza, Renzo, Stanta, Giorgio, Giorda, Giorgio, Bortot, Lucia, Bartoletti, Michele, Puglisi, Fabio, Canzonieri, Vincenzo, and Bonin, Serena
- Subjects
Oncology ,Cohort Studies ,Retrospective Studie ,Ovarian carcinoma ,80 and over ,Medicine ,Aged, 80 and over ,Ovarian Neoplasms ,BRCA1 Protein ,Obstetrics and Gynecology ,Middle Aged ,Debulking ,Prognosis ,Immunohistochemistry ,Progression-Free Survival ,Survival Rate ,Cystadenocarcinoma, Serou ,Serous fluid ,Female ,SET ,Human ,Adult ,Morphology ,medicine.medical_specialty ,Psammoma body ,Prognosi ,Cystadenocarcinoma ,Architectural pattern ,Shannon diversity index ,Internal medicine ,Humans ,HGSOC ,Progression-free survival ,Aged ,Neoplasm Staging ,Retrospective Studies ,Classic ,business.industry ,Tumor-infiltrating lymphocytes ,Malignant Ovarian Neoplasm ,Ovarian Neoplasm ,Serous ,medicine.disease ,Cystadenocarcinoma, Serous ,Heterogeneity ,Cohort Studie ,business ,Ovarian cancer - Abstract
Objective High grade serous ovarian carcinoma (HGSOC) is the most common type of malignant ovarian neoplasm and the main cause of ovarian cancer related deaths worldwide. Although novel biomarkers such as homologous recombination deficiency testing have been implemented into the clinical decision-making algorithm since diagnosis, morphological classification and immunohistochemistry analysis are essential for diagnostic purpose. This study aims at identifying histologic and clinical features that can be predictive of patients' prognosis. Methods Morphological and architectural characterization including SET (Solid-Endometroid-Transitional)/Classic features was carried out in a cohort of 234 patients analyzing 695 slides. From each slide tumor infiltrating lymphocyte (TILs), the presence of necrosis, the number of mitoses, the presence of psammoma bodies, giant cells and atypical mitoses were recorded. Morphological heterogeneity was quantified by the Shannon's diversity index (SDI) considering the percentage of each architectural pattern per patient's slide. Results The frequency of architectural patterns and morphological variables varied with respect of the surgical strategy (primary debulking surgery vs interval surgery after neoadjuvant chemotherapy). HGSOCs exhibiting SET features had a longer overall as well as progression free survival. Among SET features, pseudo-endometrioid and transitional like patterns had the best outcome, while it was heterogenous for solid pattern, that had better outcome for BRCA 1 negative and less heterogeneous tumors. In patients submitted to neoadjuvant chemotherapy a higher intratumor heterogeneity as defined by SDI was a negative independent prognostic factor. Conclusions A comprehensive histological examination considering architectural patterns and their heterogeneity can help in prognostication of HGSOCs.
- Published
- 2021
10. Is there any difference in insulin resistance status between cases of benign and malignant ovarian neoplasms? A study on surrogate markers of insulin resistance in Indonesian non-diabetic women.
- Author
-
Winarto H, Habiburrahman M, Febriana IS, Kusuma F, Nuryanto KH, Anggraeni TD, Utami TW, and Putra AD
- Abstract
The association between insulin resistance (IR) and ovarian neoplasm is little known. The present study attempted to investigate the difference in clinicopathological characteristics, metabolic parameters, and IR prevalence between benign and malignant ovarian neoplasms. The cross-sectional study involved 52 non-diabetic women with benign (n=27) and malignant (n=25) diagnoses in a tertiary hospital in Indonesia. Fasting insulin level (FIL), homeostatic model assessment of IR and β-cell dysfunction (HOMA-IR and HOMA-β), fasting IR index (FIRI), and quantitative insulin sensitivity check index (QUICKI) were used as surrogate markers to evaluate IR. Parametric and nonparametric statistical tests were employed to analyze the different parameters between the two groups. Pearson or Spearman's rank test assessed the correlation between markers and clinical variables. Results revealed that patients with benign neoplasms were younger than those with malignant neoplasms (38.63 vs. 47.40 years; P=0.003) and had a higher median body mass index (BMI) than their counterparts (22.98 vs. 18.61 kg/m
2 ; P=0.014). Different characteristics between benign and malignant neoplasm cases were found in menopausal status, ovary side affected, systolic blood pressure, and BMI classes. Endometrial cysts and mucinous carcinoma were the most often diagnosed benign and malignant neoplasms. Malignant neoplasms had a lower median HOMA-β score than benign neoplasms (49.33 vs. 75.79; P=0.011), indicating more severe β-cell dysfunction. No significant difference was observed in the prevalence of IR between benign and malignant ovarian neoplasms for the following values of each marker: FIL (25.9% vs. 12.0%), HOMA-IR (37.0% vs. 28.0%), FIRI (51.9% vs. 48.0%) and QUICKI (81.5% vs. 92.0%). The indicators of FIL, HOMA-IR, HOMA-β, FIRI, and QUICKI correlated with each other and confirmed the reliability of these surrogate markers for measuring IR status in ovarian neoplasms. In brief, benign ovarian neoplasms tended to have more IR when compared with malignant ovarian neoplasms. However, this difference was not statistically significant., Competing Interests: The authors declare that they have no competing interests., (Copyright: © Winarto et al.)- Published
- 2022
- Full Text
- View/download PDF
11. Cytokines and Prognostic Factors in Epithelial Ovarian Cancer
- Author
-
Rosekeila Simões Nomelini, Thales Parenti Silveira, Agrimaldo Martins-Filho, Eddie Fernando Candido Murta, and Millena Prata Jammal
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,Stromal cell ,ovarian neoplasm ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Stroma ,medicine ,Original Research ,peritumoral stroma ,business.industry ,Malignant Ovarian Neoplasm ,IL-2 ,Cancer ,prognostic factors ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,cytokines ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Immunohistochemistry ,Tumor necrosis factor alpha ,business ,Ovarian cancer ,Immunostaining ,TNF-alpha - Abstract
Introduction Ovarian cancer has a high mortality and delayed diagnosis. Inflammation is a risk factor for ovarian cancer, and the inflammatory response is involved in almost all stages of tumor development. Immunohistochemical staining in stroma and epithelium of a panel of cytokines in benign and malignant ovarian neoplasm was evaluated. In addition, immunostaining was related to prognostic factors in malignant tumors. Method The study group comprised 28 ovarian benign neoplasias and 28 ovarian malignant neoplasms. A panel of cytokines was evaluated by immunohistochemistry (Th1: IL-2 and IL-8; Th2: IL-5, IL-6, and IL-10; and TNFR1). Chi-square test with Yates’ correction was used, which was considered significant if less than 0.05. Results TNFR1, IL-5, and IL-10 had more frequent immunostaining 2/3 in benign neoplasms compared with malignant tumors. Malignant tumors had more frequent immunostaining 2/3 for IL-2 in relation to benign tumors. The immunostaining 0/1 of IL 8 was more frequent in the stroma of benign neoplasms compared with malignant neoplasms. Evaluation of the ovarian cancer stroma showed that histological grade 3 was significantly correlated with staining 2/3 for IL-2 ( P = 0.004). Women whose disease-free survival was less than 2.5 years had TNFR1 stromal staining 2/3 ( P = 0.03) more frequently. Conclusion IL-2 and TNFR1 stromal immunostaining are related prognostic factors in ovarian cancer and can be the target of new therapeutic strategies.
- Published
- 2016
12. Rupture of a malignant ovarian tumor in pregnancy presenting as acute abdomen.
- Author
-
Malhotra, Neena, Sumana, Gurunath, Singh, Aprajita, Deka, Deepika, and Mittal, Suneeta
- Subjects
- *
OVARIAN tumors , *OVARIAN cysts , *ORGAN rupture , *PREGNANCY , *ACUTE abdomen - Abstract
Ovarian neoplasms in pregnancy are usually asymptomatic rarely leading onto complications. A 30-year-old G2 P1+0+0+1 was referred at 30 weeks of pregnancy with an ultrasound diagnosis of a large multicystic ovarian cyst with no solid areas, ascites or evidence of metastasis. Antenatal corticosteroid was administered and she was advised to follow-up with reports of tumor markers. She presented a week later with acute pain abdomen and breathlessness. Clinical examination revealed a relaxed uterus and ultrasound was suggestive of rupture of the ovarian cyst. Exploratory laparotomy revealed a ruptured left mucinous ovarian cyst with no evidence of solid areas or metastasis. Left ovariotomy with infracolic omentectomy and concurrent cesarean section was done. A healthy male baby of weight 1.880 kg was delivered. Histopathology revealed stage-1c mucinous cyst adenocarcinoma of left ovary. This was followed-up, with a complete surgery done after a month. She is now receiving postoperative chemotherapy. This is the first reported case of a ruptured malignant ovarian tumor in pregnancy. Torsion or rupture of ovarian masses is an important differential diagnosis of abdominal or pelvic pain during pregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
13. Large twisted ovarian fibroma in menopausal women: a case report
- Author
-
Mohamed Oukabli, Jaouad Kouach, Mohammed Dehayni, Ihsan Hakimi, Driss Rahali Moussaoui, and Majdouline Boujoual
- Subjects
medicine.medical_specialty ,Abdominal pain ,Ovary ,Case Report ,Fibroma ,Diagnosis, Differential ,medicine ,Humans ,Gynecology ,Ovarian Neoplasms ,Ovarian fibroma ,lcsh:R5-920 ,Postmenopausal women ,Surgical approach ,postmenopausal ,business.industry ,Malignant Ovarian Neoplasm ,lcsh:Public aspects of medicine ,torsion ,lcsh:RA1-1270 ,General Medicine ,Middle Aged ,medicine.disease ,Abdominal Pain ,Postmenopause ,stomatognathic diseases ,medicine.anatomical_structure ,Female ,Radiology ,Differential diagnosis ,medicine.symptom ,business ,lcsh:Medicine (General) - Abstract
Ovarian fibroma is the most common benign solid tumors of the ovary, commonly misdiagnosed as uterine fibromaor as malignant ovarian tumors. It occurs generally in older perimenopausal and postmenopausal women. Occasionally large fibromas may undergo torsion causing acute abdominal pain. Doppler Ultrasonographyimaging is the choice study. CT and MRI are often needed for further characterization and differentiation from other solid ovarian masses. The choice treatment is surgical removal with intraoperative frozensection. Immunohistochemicalanalysis is recommended to rule out the differential diagnosis. Here we present a case of a postmenopausal woman with a large twisted ovarian fibroma reflecting diagnostic and management difficulties including potential misdiagnosis of the tumor as a malignant ovarian neoplasm that may influence the surgical approach.
- Published
- 2015
14. Bilateral Serous Psammocarcinoma of Ovary: Rare Variant Low Grade Serous Carcinoma
- Author
-
Saubhagya Kumar Jena, Pritinanda Mishra, Vandana Mohapatra, and Sweta Singh
- Subjects
medicine.medical_specialty ,Pathology ,Serous carcinoma ,business.industry ,Exploratory laparotomy ,Malignant Ovarian Neoplasm ,medicine.medical_treatment ,Obstetrics and Gynecology ,Case Report ,medicine.disease ,Debulking ,lcsh:Gynecology and obstetrics ,Serous fluid ,medicine.anatomical_structure ,Psammoma Body Formation ,Peritoneum ,medicine ,Histopathology ,business ,lcsh:RG1-991 - Abstract
Serous psammocarcinoma is a rare variant of serous carcinoma arising from either ovary or peritoneum, characterized by massive psammoma body formation, low grade cytologic features, and invasiveness. Its clinical behavior is similar to serous borderline tumors with relatively favorable prognosis. We report herein a case of a 60-year-old postmenopausal woman who presented with abdominal distension. Contrast enhanced computed tomography (CECT) revealed calcified pelvic masses with ascites. Elevated serum CA-125 (970 U/mL) suggested malignant ovarian neoplasm. Patient underwent exploratory laparotomy with primary debulking surgery. Histopathology showed bilateral serous psammocarcinoma of ovary with invasive implants on omentum. Adjuvant chemotherapy was advised in view of advanced stage disease, although its benefits are poorly defined due to rarity of the tumor. However, patient opted out of it and is now on follow-up.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.